Progastrin inhibitors in the treatment of colon cancer

Abstract

The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and / or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin / Tcf-4-mediated transcriptional pathway is constitutively active.

Description

field of invention [0001] The present invention relates to methods and compositions for the treatment and prevention of colorectal cancer, adenomatous polyposis and metastasis. Background of the invention [0002] In 66% of cases, tumorigenesis of the human colon involved somatic mutations in the tumor suppressor gene adenomatous polyposis coli (APC) or in the β-catenin gene (average values ​​calculated from the following references: ( Conlin et al., 2005; De Filippo et al., 2002; Huang et al., 1996; Johnson et al., 2005; Kim et al., 2003; Luchtenborg et al., 2005; Mikami et al., 2006; Morin et al., 1997; Powell Rowan et al., 2000; Segditsas and Tomlinson, 2006; Shitoh et al., 2004; Smith et al., 2002; Sparks et al., 1998; Suraweera et al., 2006; Takayama et al., 2001)). These mutations are considered early events in colorectal carcinogenesis occurring in patients with sporadic colorectal cancer. Germline mutations in the APC gene also respond to familial polyposis coli, a...

AI Technical Summary

Problems solved by technology

[0012] To date, effective and specific modalities for the treatment and / or prevention of colorectal cancer, metastases and adenomatous polyposis are lacking

Images